GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (FRA:CZTA) » Definitions » ROE % Adjusted to Book Value

Checkpoint Therapeutics (FRA:CZTA) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Checkpoint Therapeutics ROE % Adjusted to Book Value?

Checkpoint Therapeutics's ROE % for the quarter that ended in Sep. 2024 was 0.00%. Checkpoint Therapeutics's PB Ratio for the quarter that ended in Sep. 2024 was N/A. Checkpoint Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was N/A.


Checkpoint Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Checkpoint Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkpoint Therapeutics ROE % Adjusted to Book Value Chart

Checkpoint Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only - -16.75 -22.71 - -

Checkpoint Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Checkpoint Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Checkpoint Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Checkpoint Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkpoint Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Checkpoint Therapeutics's ROE % Adjusted to Book Value falls into.



Checkpoint Therapeutics ROE % Adjusted to Book Value Calculation

Checkpoint Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Checkpoint Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Checkpoint Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Checkpoint Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Checkpoint Therapeutics Business Description

Traded in Other Exchanges
Address
95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Checkpoint Therapeutics Headlines

No Headlines